Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

With APLLTD's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 1.593000
forwardPE 19.887928
debtToEquity 28.004000
earningsGrowth 0.207000
revenueGrowth 0.159000
grossMargins 0.720340
operatingMargins 0.125450
trailingEps 32.300000
forwardEps 43.500000

APLLTD's current ratio, being 1.593, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, APLLTD is well-equipped to meet its immediate financial obligations without any difficulties.
Alembic Pharmaceuticals Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
APLLTD's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
Positive earnings and revenue growth for APLLTD suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
APLLTD's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in APLLTD's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

Over time, APLLTD's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for APLLTD.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


There were 20 buy transactions of APLLTD stock, with market price at 881.7800018310547 per share.No buy transactions occurred during the period under consideration.More sells than buys at APLLTD's current price levels suggest a potential downside. If this selling trend persists, it could trigger further price declines, as increased selling often reflects investor pessimism about the stock's future prospects.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


APLLTD has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view APLLTD as a reliable choice for their money, offering a promising avenue for future growth and financial gains.